Active drug metabolites and renal failure

Area of Science:

• Pharmacology
• Nephrology
• Drug Metabolism

Background:

• Drugs can be biotransformed into active metabolites in the human body.
• These active metabolites may accumulate in patients with end-stage renal disease (ESRD) if kidney excretion is their primary elimination route.
• Accumulation can occur even for minor metabolites if they are not further biotransformed or if their metabolic pathways are inhibited in uremia.

Purpose of the Study:

• To discuss the clinical consequences of active drug metabolite accumulation in patients with renal failure.
• To explain the high incidence of adverse drug reactions in renal failure partly due to metabolite accumulation.
• To provide examples of active drug metabolites that do not accumulate in renal failure.

Main Methods:

• Review of existing literature on drug biotransformation and renal excretion.
• Analysis of pharmacokinetic data for specific drugs and their metabolites in renal failure.
• Clinical case discussions and examples.

Main Results:

• Active metabolites of certain drugs (e.g., procainamide, meperidine, clofibrate, allopurinol, sulfadiazine, nitrofurantoin) can accumulate in patients with ESRD.
• This accumulation is linked to the high incidence of adverse drug reactions observed in this patient population.
• Some active metabolites do not accumulate due to efficient further biotransformation pathways that are not inhibited in uremia.

Conclusions:

• The accumulation of active drug metabolites is a significant factor contributing to adverse drug reactions in patients with renal failure.
• Understanding metabolite pharmacokinetics is crucial for safe drug prescribing in patients with impaired renal function.
• Further research into drug metabolism and excretion in renal disease is warranted.